Author

K. C. Wood

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Research Focus:drug response / drug discovery· 5 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Approach:genetic perturbation / CRISPR· 2 Assay:imaging· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Barrera· 2 shared E. D. SoRelle· 2 shared K. R. Singleton· 2 shared M. A. Luftig· 2 shared T. E. Reddy· 2 shared A. E. Stewart· 1 shared A. K. Decker· 1 shared A. M. Pendergast· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 9 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Barrera

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Drug dependence in cancer is exploitable by optimally constructed treatment holidays

J. Maltas, K. R. Singleton, K. C. Wood, K. B. Wood

This paper shows that drug-dependent cancer cells can be targeted by optimized treatment holidays, reducing population growth through adaptive therapy strategies.

Nature Ecology & Evolution · Nov 27, 2023Peer-reviewedCancer Biology

MCB-613 exploits a collateral sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer through covalent inhibition of KEAP1

C. F. Bassil, G. R. Anderson, B. Mayro, K. N. Askin, P. S. Winter, S. Gruber, T. M. Hall, J. P. Hoj, C. Cerda-Smith, H. M. Hutchinson, S. T. Killarney, K. R. Singleton, L. Qin, K. Jubien-Girard, C. Favreau, , K. C. Wood

The paper identifies MCB-613 as a compound that targets KEAP1 in EGFR inhibitor-resistant NSCLC cells, exploiting its selective essentiality through covalent inhibition.

bioRxiv · Jan 17, 2023 · PreprintCancer Biology

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers

D. P. Nussbaum, C. A. Martz, A. M. Waters, A. Barrera, J. C. Rutter, C. G. Cerda-Smith, A. E. Stewart, C. Wu, M. Cakir, C. B. Levandowski, D. E. Kantrowitz, S. J. McCall, M. Pierobon, E. Petricoin, J. J. Smith, , K. C. Wood

This study shows that Mediator kinase inhibition prevents resistance to ERK/MAPK inhibitors in KRAS-mutant cancers by blocking transcriptional plasticity.

bioRxiv · Sep 17, 2022 · PreprintCancer Biology

Cooperative regulation of coupled oncoprotein translation and stability in triple-negative breast cancer by EGFR and CDK12

H. X. Ang, N. Sutiman, X. L. Deng, L. C. Bartelt, Q. Chen, A. Barrera, J. Lin, J. Z. Sheng, I. C. McDowell, T. E. Reddy, C. V. Nicchitta, K. C. Wood

The paper identifies CDK12 inhibition as a strategy to enhance EGFR blockade efficacy in TNBC by targeting translation and stability of oncoproteins like MYC through 4E-BP1 and CCR4-NOT complex.

bioRxiv · Mar 3, 2021 · PreprintCancer Biology

Comparing instance segmentation methods for analyzing clonal growth of single cells in microfluidic chips

E. D. SoRelle, S. White, B. Yellen, K. C. Wood, M. A. Luftig, C. Chan

The paper compares segmentation methods for analyzing clonal growth in microfluidic chips, finding unsupervised learning methods more accurate and flexible than supervised approaches.

bioRxiv · Dec 31, 2020 · PreprintBioengineering

Massively parallel quantification of phenotypic heterogeneity in single cell drug responses

B. B. Yellen, J. S. Zawistowski, E. A. Czech, C. I. Sanford, E. D. SoRelle, M. A. Luftig, Z. G. Forbes, K. C. Wood, J. Hammerbacher

The paper develops a single-cell phenotyping tool to measure clonal properties at scale, applying it to study drug responses in AML clones and identifying rare resistance phenotypes.

bioRxiv · Dec 18, 2020Bioengineering

Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy

R. J. Kishton, S. J. Patel, S. K. Vodnala, A. K. Decker, Y. Patel, M. Sukumar, T. N. Yamamoto, Z. Yu, M. Ji, A. N. Henning, D. Gurusamy, D. C. Palmer, W. Lo, A. Pasetto, P. Malekzadeh, , N. P. Restifo

This study identifies genes that tumor cells use to resist T cell killing and shows that inhibiting BIRC2, ITGAV, or DNPEP enhances T cell-mediated tumor destruction.

bioRxiv · Nov 18, 2019 · PreprintImmunology